CAR-T Cells for HIV Infection
Phase 1/2
18
about 8.8 years
18–65
2 sites in CA
About this study
This trial is testing a new treatment called LVgp120duoCAR-T cells to see if it can help people with HIV. The treatment involves pausing HIV medications temporarily after receiving the CAR-T cells. Participants will be given either a low or high dose of these cells, and some may also receive cyclophosphamide before the infusion.
Based on ClinicalTrials.gov records.
What participants do
- 1.Analytic Treatment Interruption
- 2.Receive LVgp120duoCAR-T cells, high dose
- 3.Receive LVgp120duoCAR-T cells, low dose
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands)
infusion
Primary: Number of participants reporting a new Grade 3 or greater adverse event that is definitely, probably, or possibly related to study treatment within 1 year of product administration.
Immune, Infectious